* NantHealth Inc NH.OQ NH.O is expected to show a rise in
quarterly revenue when it reports results on May 6.
* The Culver City, California-based company is expected to
report a 0.8% increase in revenue to $18.33 million from
$18.18 million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for NantHealth Inc is for a
loss of 7 cents per share. For the same quarter last year, the
company reported a loss of 6 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for NantHealth Inc
is $3.75, about 32.3% above its last closing price
of $2.54.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 -0.08 -0.08 -0.06 Beat 25
Sep. 30 2020 -0.07 -0.06 -0.07 Missed -7.7
Jun. 30 2020 -0.06 -0.05 -0.07 Missed -27.3
Mar. 31 2020 -0.06 -0.06 -0.06 Met 7.7
Dec. -0.06 -0.05 -0.04 Beat 27.3
31 2019
Sep. 30 2019 -0.03 -0.03 -0.07 Missed -100
Jun. 30 2019 -0.09 -0.09 -0.04 Beat 55.6
Mar. 31 2019 -0.10 -0.10 -0.10 Met 0
This summary was machine generated May 5 at 02:00 GMT. All
figures in US dollars unless otherwise stated